| Tivan Limited (TVN) ORDINARY FULLY PAID |
Materials |
$737 |
Further Ultra High-Grade Fluorite assays at Sandover
|
16 Jun 2025 8:30AM |
$0.091 |
$0.325 |
risen by
257.14%
|
|
TVN - Price-sensitive ASX Announcement
Full Release
Key Points
- Tivan Limited reported further ultra high-grade fluorite assay results from the Sandover Project.
- Recent rock chip samples have returned several assays exceeding 90% CaF2.
- The results confirm Sandover's potential as a world-class fluorite asset.
- The geological context and exploration methodologies are described in detail.
- The company plans to undertake further drilling and resource definition activities.
- Management emphasizes the strategic importance of these results for project development.
- The report outlines potential for global significance and future partnerships.
- The announcement supports Tivan’s strategy to advance Sandover as a major fluorite project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Evolution Mining Limited (EVN) ORDINARY FULLY PAID |
Materials |
$26,485 |
June Quarter 2025 Conference Call Notification
|
16 Jun 2025 8:30AM |
$9.200 |
$13.040 |
risen by
41.74%
|
|
| Flight Centre Travel Group Limited (FLT) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,214 |
Update - Notification of buy-back - FLT
|
16 Jun 2025 8:30AM |
$12.430 |
$10.740 |
fallen by
13.60%
|
|
| GTN Limited (GTN) ORDINARY FULLY PAID |
Communication Services |
$44 |
Update - Notification of buy-back - GTN
|
16 Jun 2025 8:30AM |
$0.620 |
$0.230 |
fallen by
62.90%
|
|
| Buxton Resources Limited (BUX) ORDINARY FULLY PAID |
Materials |
$19 |
Fieldwork Commences at Centurion
|
16 Jun 2025 8:30AM |
$0.040 |
$0.045 |
risen by
12.50%
|
|
| Locate Technologies Limited (LOC) ORDINARY FULLY PAID |
Information Technology |
- |
ATM Facility - Capital Raise
|
16 Jun 2025 8:30AM |
$0.140 |
$0.056 |
fallen by
60%
|
|
LOC - Price-sensitive ASX Announcement
Full Release
Key Points
- Locate Technologies Limited is conducting a capital raise to fund ATM facility expansion.
- The capital will be used to increase ATM installations and improve technology infrastructure.
- New shares will be issued to both existing and new investors as part of the capital raise.
- The raised funds are aimed at accelerating growth and expanding LOC's market presence.
- Operational capacity and technology platform enhancements are major focuses of the investment.
- The capital raise reflects LOC's strategy to deliver shareholder value and address demand for cash access.
- Specific details of the share offering and fundraising structure are provided in the announcement.
- The initiative underlines the company's commitment to growth in the ATM sector.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nyrada Inc (NYR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$138 |
Non-Deal Investor Presentation
|
16 Jun 2025 8:30AM |
$0.200 |
$0.565 |
risen by
182.50%
|
|
| Waypoint REIT Limited (WPR) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,620 |
Update - Notification of buy-back - WPR
|
16 Jun 2025 8:30AM |
$2.640 |
$2.480 |
fallen by
6.06%
|
|
| Galileo Mining Ltd (GAL) ORDINARY FULLY PAID |
Materials |
$32 |
Palladium Platinum Assays Display Potential for Discovery
|
16 Jun 2025 8:30AM |
$0.120 |
$0.160 |
risen by
33.33%
|
|
GAL - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant palladium and platinum assays reported from Norseman project.
- Assays include notable values of palladium, platinum, and nickel from Jimberlana and Mission Sill prospects.
- Results indicate extensive mineralisation with zones open along strike and at depth.
- Potential for new discovery in Western Australia identified.
- Supports Galileo Mining Ltd's strategy to target palladium-platinum and nickel sulphide mineralisation.
- Further drilling programs planned to expand and follow up on current results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NAOS Ex-50 Opportunities Company Limited (NAC) ORDINARY FULLY PAID |
Financials |
$26 |
Update - Notification of buy-back - NAC
|
16 Jun 2025 8:29AM |
$0.480 |
$0.575 |
risen by
19.79%
|
|
| Karoon Energy Ltd (KAR) ORDINARY FULLY PAID |
Energy |
$1,564 |
Update - Notification of buy-back - KAR
|
16 Jun 2025 8:29AM |
$1.985 |
$2.200 |
risen by
10.83%
|
|
| Worley Limited (WOR) ORDINARY FULLY PAID |
Industrials |
$5,786 |
Update - Notification of buy-back - WOR
|
16 Jun 2025 8:29AM |
$13.470 |
$11.730 |
fallen by
12.92%
|
|
| Thorney Opportunities Ltd (TOP) ORDINARY FULLY PAID |
Financials |
$85 |
Update - Notification of buy-back - TOP
|
16 Jun 2025 8:29AM |
$0.640 |
$0.500 |
fallen by
21.88%
|
|
| Capral Limited (CAA) ORDINARY FULLY PAID |
Materials |
$201 |
Update - Notification of buy-back - CAA
|
16 Jun 2025 8:29AM |
$10.550 |
$12.500 |
risen by
18.48%
|
|
| IRIS Metals Limited (IR1) ORDINARY FULLY PAID |
Materials |
$24 |
Notification of cessation of securities - IR1
|
16 Jun 2025 8:29AM |
$0.135 |
$0.084 |
fallen by
37.78%
|
|
| Cadence Capital Limited (CDM) ORDINARY FULLY PAID |
Financials |
$223 |
Update - Notification of buy-back - CDM
|
16 Jun 2025 8:29AM |
$0.640 |
$0.750 |
risen by
17.19%
|
|
| Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID |
Health Care |
$82 |
Pathological Complete Response in Pancreatic Cancer Trial
|
16 Jun 2025 8:29AM |
$0.057 |
$0.160 |
risen by
180.70%
|
|
ATX - Price-sensitive ASX Announcement
Full Release
Key Points
- Amplia Therapeutics released interim data from its ACCENT Phase 2 pancreatic cancer trial.
- The trial evaluates narmafotinib (AMP945), a FAK inhibitor, in combination with chemotherapy.
- Three of nine patients (33%) achieved pathological complete response (pCR) after combination therapy.
- Typical pCR rates in pancreatic cancer are under 10%, making these results notable.
- No new safety concerns were identified for narmafotinib in combination with standard chemotherapy.
- pCR is linked to improved overall survival outcomes in pancreatic cancer.
- Results provide rationale for continued development of narmafotinib in pancreatic and other solid tumors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Computershare Limited (CPU) ORDINARY FULLY PAID |
Industrials |
$17,537 |
Update - Notification of buy-back - CPU
|
16 Jun 2025 8:29AM |
$40.650 |
$30.320 |
fallen by
25.41%
|
|
| Tolu Minerals Limited (TOK) ORDINARY FULLY PAID |
Materials |
$374 |
Exploration Commences in the 120 Vein-Kimono Vein Area
|
16 Jun 2025 8:29AM |
$0.850 |
$1.450 |
risen by
70.59%
|
|
TOK - Price-sensitive ASX Announcement
Full Release
Key Points
- Tolu Minerals Limited has started exploration in the 120 Vein-Kimono Vein Area at the Tolukuma Gold Project.
- The exploration program includes geological mapping, soil and rock sampling, and trenching activities.
- Initial fieldwork has confirmed the presence of significant quartz-sulphide veins with visible gold mineralization.
- The company is targeting both gold and silver mineralization within known and newly identified vein systems.
- Exploration activities are designed to upgrade the understanding of mineralized zones and refine drill targets.
- Tolu Minerals is actively engaging with local communities and ensuring compliance with environmental and regulatory standards.
- The company anticipates that the results from the exploration program will inform future drilling campaigns and resource estimation.
- The announcement reiterates Tolu Minerals' commitment to responsible exploration and sustainable development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NobleOak Life Limited (NOL) ORDINARY FULLY PAID |
Financials |
$118 |
Becoming a substantial holder
|
16 Jun 2025 8:29AM |
$1.600 |
$1.270 |
fallen by
20.63%
|
|
| Viva Leisure Limited (VVA) ORDINARY FULLY PAID |
Consumer Discretionary |
$153 |
Update - Notification of buy-back - VVA
|
16 Jun 2025 8:29AM |
$1.340 |
$1.550 |
risen by
15.67%
|
|
| Camplify Holdings Limited (CHL) ORDINARY FULLY PAID |
Industrials |
$21 |
Ceasing to be a substantial holder
|
16 Jun 2025 8:28AM |
$0.300 |
$0.255 |
fallen by
15%
|
|
| Nido Education Limited (NDO) ORDINARY FULLY PAID |
Consumer Discretionary |
$85 |
Update - Notification of buy-back - NDO
|
16 Jun 2025 8:28AM |
$0.710 |
$0.375 |
fallen by
47.18%
|
|
| EMvision Medical Devices Limited (EMV) ORDINARY FULLY PAID |
Health Care |
$169 |
EMVision Awarded $5m Non-Dilutive Government Grant
|
16 Jun 2025 8:28AM |
$1.790 |
$1.815 |
risen by
1.40%
|
|
EMV - Price-sensitive ASX Announcement
Full Release
Key Points
- EMVision awarded $5 million non-dilutive MRFF government grant.
- Funding to advance portable brain imaging technology for rapid stroke diagnosis.
- Grant supports product development, clinical validation, and commercialization.
- Technology targets hospital and pre-hospital use for improved stroke care.
- EMVision’s device aims to provide rapid neuroimaging at the point of care.
- Collaboration planned with clinical and research partners.
- Significant endorsement of EMVision’s innovation by Australian government.
- Funding to accelerate timelines for bringing device to market.
- Potential to improve patient outcomes and healthcare efficiencies.
- Grant is non-dilutive, preserving shareholder value.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,784 |
Notification of cessation of securities - NWS
|
16 Jun 2025 8:28AM |
$48.310 |
$42.930 |
fallen by
11.14%
|
|
Call 1300 880 160
Start a chat
Schedule a call
